CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH) announced that its CEO will issue a letter to shareholders on December 2, 2025, outlining key initiatives to advance the company's strategic direction. The letter will provide updates on the company's S-1 filing, which is intended to transition CTT into a full SEC reporting company, thereby granting access to funding from its equity line of credit and accelerating growth by monetizing its patents.
In addition to financial updates, the CEO's letter will cover ongoing operational initiatives, including steps toward establishing manufacturing capabilities. Shareholders will also receive information on strategic partners aligned with CTT's commercialization strategy, as well as an update on the recent submission of a peer-reviewed scientific manuscript that highlights the scientific foundation behind what the company describes as a transformative technology in therapeutic drug delivery.
For more details, view the original release on NewMediaWire.
